Askela SRL
The score of Askela shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +55 % Total assets +50 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Askela's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2020 | |
|---|---|---|---|---|---|
| Net result | 28,346 € | ||||
| Equity | 291,736 € | ||||
| Cash | 65,895 € | ||||
| EBITDA | 24,747 € | ||||
| Total assets | 293,294 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jul 2026
- Year ended 31 Dec 2024filed on 26 Aug 2025
- Year ended 30 Jun 2023filed on 31 Jan 2024
- Year ended 30 Jun 2022filed on 31 Jan 2023
- Year ended 30 Jun 2020filed on 09 Feb 2021
Askela's financial analysis
- Solvency99.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Askela
Askela's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0835.952.928
- VAT number
- BE0835952928
- Peppol
- Registered · 0208:0835952928 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 27 Apr 2011
- Registered office
- 7950 Chièvres
- Latest accounts
- 2025 · filed on 23 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Askela (SRL) has been based in Chièvres since 2011, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 28,346 € and equity of 291,736 €; its revenue is not published. Its solvency stands at 99.5%, above the median of its sector (41.5%).
Companies similar to Askela
Companies in the same business, of comparable size and area, outside its group.
- Aksa Pharma Retail sale of pharmaceutical products Brussels · balance sheet 293,776 €
- Pharmacie Gendebien A Ninane Retail sale of pharmaceutical products Chaudfontaine · balance sheet 292,681 €
- LES Iles D'OR Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet 291,796 €
- Theunissen-DE Neve Retail sale of pharmaceutical products Aalst · balance sheet 291,003 €
- AONA Retail sale of pharmaceutical products Roeselare · balance sheet 290,456 €
- ACE Pharma Retail sale of pharmaceutical products Fexhe-le-Haut-Clocher · balance sheet 289,661 €
- Leveugle Retail sale of pharmaceutical products Deinze · balance sheet 297,608 €
- Warquigniespharma Retail sale of pharmaceutical products Colfontaine · balance sheet 299,659 €
Frequently asked questions about Askela
What is the revenue of Askela?
Askela files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Askela?
In Belgium, the VAT number is the company number prefixed with BE: BE0835952928 for Askela, if the company is VAT-registered. Its company number (CBE) is 0835.952.928.
Where is the registered office of Askela?
According to the CBE register, the registered office of Askela is in 7950 Chièvres.
What is the equity of Askela?
At the close of the 2025 financial year, the equity of Askela amounts to 291,736 €, a solvency of 99.5% of total assets.
Who manages Askela?
The register lists 3 active mandates at Askela. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Askela
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →